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Abstract 
 
Depressed mood often co-exists with frequent drug and alcohol use. This trial 
examined the feasibility of screening, recruiting, randomizing and engaging drug 
and alcohol users in psychological interventions for depression symptoms. A total 
of 50 patients involved in community drugs and alcohol treatment (CDAT) were 
randomly allocated to behavioral activation delivered by psychological therapists (n 
= 23) or to cognitive behavioral therapy based self-help introduced by CDAT 
workers (n = 27). We examined recruitment and engagement rates, as well as 
changes in depression (PHQ-9) symptoms and changes in percent days abstinent 
(PDA within last month) at 24 weeks follow-up. The ratio of screened to recruited 
participants was 4 to 1, and the randomization schedule successfully generated 2 
groups with comparable characteristics. Follow-up was possible with 78% of 
participants post-treatment. Overall engagement in psychological interventions was 
low; only 42% of randomized participants attended at least 1 therapy session. 
Patients offered therapy appointments co-located in CDAT clinics were more likely 
to engage with treatment (Odds ratio = 7.14, p = .04) compared to those offered 
appointments in community psychological care clinics. Intention-to-treat analyses 
indicated no significant between-group differences at follow-up in mean PHQ-9 
change scores (p = .59) or in PDA (p = .08). Overall, it was feasible to conduct a 
pragmatic trial within busy CDAT services, maximizing external validity of study 
results. Modest and comparable improvements in depression symptoms over time 
were observed for participants in both treatment groups. 
 
 
Highlights 
 ? It was feasible to apply a high volume, stepwise screening method in routine 
addiction treatment ? Patients offered therapy appointments ‘co-located’ in addiction clinics were 
more likely to engage with treatment compared to those offered ‘parallel’ 
appointments in other mental health clinics  ? Poly-substance users were less likely to engage with treatment ? No significant differences were found between behavioral activation and CBT 
based guided self-help in terms of depression symptom reductions or 
percent days abstinence ? Both interventions were associated with moderate depression symptom 
improvements over time 
 
 
Key words:  depression, comorbidity, drugs, alcohol, cognitive behavioral therapy 
 
 
Study acronym: COBID (COmorbidity and Brief Interventions for Depression) 
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COBID trial manuscript 
 3 
 
 
1. Introduction 
 
There is considerable evidence that common mental health problems like 
depression and anxiety often co-occur with problematic alcohol and drug use 
(Marsden, Gossop, Stewart, Rolfe & Farrell, 2000; Strathdee, et al., 2002; Weaver 
et al., 2003). People who frequently use substances are 2 times at greater risk of 
having a comorbid depression or anxiety disorder, and this increases to 5 times 
greater risk for dependent substance users (Merikangas et al., 1998). This 
combination of problems often complicates treatment and can result in greater 
functional impairment (Johnson et al., 1995), reduced treatment adherence 
(Carroll, Power, Bryant, & Rounsaville, 1993; Ford, Snowden & Walser, 1991), poor 
health outcomes (Hasin et al., 2002; McKay et al., 2002) and increased risk of 
suicide (Harris & Barraclough, 1997).  
The detection of such comorbid disorders has historically been inconsistent 
in routine treatment in the United Kingdom (Weaver et al., 2003). Consequently, it 
has been estimated that only 1 in 5 people (20%) involved with community drugs 
services tend to access mental health treatment (Marsden et al., 2000).  Even if 
comorbid mental health problems are adequately detected, treatment options for 
this client group seem to have fairly modest benefits. Pharmacological treatments 
for depression in alcohol and drug users appear to have mixed evidence, with some 
reviews that indicate a beneficial effect (Iovieno, Tedeschini, Bentley, Evins, & 
Papakostas, 2011;  Nunes & Levin, 2004) and other reviews that question their 
efficacy (Lingford-Hughes, Welch & Nutt, 2012; Pedrelli et al., 2011; Torrens, 
Fonseca, Mateu & Farré, 2005). In view of such evidence, exploring the potential of 
psychological treatments may be a fruitful avenue for research and practice.  
Published trials of psychological treatments for depression and anxiety in 
substance users suggest that cognitive behavioral therapy (CBT) may be an 
effective treatment (Baillie & Sannibale, 2007; Baker et al., 2010; Brown et al., 
2006; Brown, Evans, Miller, Burgess & Mueller, 1997; Hides, Samet, & Lubman, 
2010; Hunter et al., 2012; Kay-Lambkin, Baker, Lewin & Carr, 2009; Kay-
Lambkin, Baker, Kelly & Lewin, 2011; Watkins, Paddock, Zhang, & Wells, 2006; 
Watkins et al., 2011). There is, however, scarce research on the application of 
contemporary behavioral activation (BA) models of treatment in clinical populations 
of substance users. BA is an intervention that alleviates depression by focusing 
primarily on changing maladaptive behaviors (such as avoidance, rumination, 
coping strategies that have unintended negative consequences) that are posited to 
maintain a cycle of low mood (Martell, Addis, & Jacobson, 2001). BA shares some 
conceptual underpinnings with CBT such as behavior modification and learning 
theories, but it does not emphasize the direct modification of thoughts and beliefs 
as in CBT. The efficacy of BA for the treatment of depression in adults has been 
endorsed by several meta-analyses of clinical trials (Cuijpers, van Straten, & 
Warmerdam, 2007; Ekers, Richards, & Gilbody, 2008; Ekers et al., 2014; 
Mazzucchelli, Kane, Rees, 2009). However, to our knowledge, only one published 
controlled trial has tested the efficacy of BA with a clinical sample of dependent 
substance users (Daughters et al., 2008). This trial concluded that augmenting 
inpatient addiction treatment with BA leads to greater reductions in depression 
symptoms compared to usual inpatient care.  
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Considering the prevalence and impact of common mental health problems 
in drug and alcohol users, and the emerging evidence-base for cognitive and 
behavioral interventions, we conducted a trial to investigate the feasibility of 
delivering BA and CBT based guided self-help for depression as part of routine 
community drugs and alcohol treatment (CDAT). Given our focus on feasibility, the 
study design also aimed to assess whether co-locating BA within CDAT clinics may 
enhance engagement with therapy, by comparison to offering this intervention in 
external mental health clinics as in usual practice. This aspect of the trial was 
informed by policy guidelines (Department of Health, 2002) that promote 
integration and close partnership work between substance use and mental health 
professionals. Though this seems like a sensible policy, we are not aware of 
empirical evidence specifically supporting the co-location of psychological 
interventions within CDAT settings and we therefore considered it worthy of further 
investigation. 
 
2. Methods 
 
2.1. Study design 
This was a phase I feasibility randomized controlled trial embedded within 
CDAT services in Leeds, United Kingdom. Consistent with the medical research 
council (MRC) guidelines for the development of complex interventions (Craig et al., 
2008), the central objective was to examine the feasibility of screening, recruiting, 
randomizing and engaging patients in psychological interventions for depression 
symptoms. In this context, we defined engagement as having attended at least one 
therapy session post-randomization. As part of the design, half of the patients 
assigned to BA were offered appointments in clinics co-located in CDAT services, 
and the other half were offered appointments in external clinics - which we refer to 
as ‘parallel’ care. A secondary objective was to compare the proportion of cases that 
engaged with BA treatment in the co-located versus parallel clinics. Finally, we also 
aimed to estimate comparative effect sizes to inform the sample size calculation for 
a fully powered efficacy trial.  
Ethical approval for this trial was granted by a National Health Service 
research ethics committee (REC Reference: 12/YH/0096, Registration: 
ISRCTN26937594). 
 
2.2. Inclusion criteria 
Outpatients accessing five CDAT teams were screened for eligibility to take 
part in the trial. Patients were included if (a) they were currently registered with 
CDAT and engaged with these services within the last month; (b) they screened 
positive for clinically significant depression symptoms as defined by the Patient 
Health Questionnaire (PHQ-9); (c) they had mild-to-moderate symptoms of alcohol 
or drug dependence as defined by the Severity of Dependence Scale (SDS). Patients 
who did not meet the above criteria were excluded from the study, as were those 
who had a current diagnosis of a psychotic, bipolar, or severe anxiety disorder (this 
was established based on clinical records, screening tools and interview). People 
who were in treatment but were now free from psychoactive substances (abstinent 
for at least 4 weeks) were excluded as we were interested in the feasibility of 
recruiting, retaining and providing psychological treatment for those who were 
current and recent substance users. 
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2.3. Screening, recruitment and randomization 
A stepwise screening and recruitment method was applied during 18 
months, using the following steps:  
 
(1) All patients currently in treatment in the participating services completed 
the Treatment Outcomes Profile (TOP) questionnaire as part of regular 
outcome monitoring.  
(2) Those that screened positive for a possible common mental health problem 
using the TOP psychological health scale (TOP item 4a) were then 
immediately screened with more specific depression (PHQ-9), anxiety (GAD-
7) and severity of dependence (SDS) questionnaires by their case managers.  
(3) Those who met inclusion criteria based on step 2 were informed about the 
study by their case manager and consent to be contacted by the study co-
ordinator was obtained.  
(4) The contact details of consenting patients were passed on to the study co-
ordinator who contacted them to conduct an eligibility and recruitment 
interview. Informed consent was obtained for participation in the trial at the 
time of these interviews. 
 
The first 3 steps were conducted in routine practice by the usual case 
managers and support workers, and step 4 was conducted by the study co-
ordinator. The co-ordinator was a researcher with experience in screening and 
diagnostic assessment, who was not involved in the direct delivery of the trial 
interventions. In order to minimize the chances that case managers in CDAT teams 
may be selective about the patients they approached for mental health screening, 
the study co-ordinator performed regular searches in the clinical database to 
identify potential participants who had recently completed a TOP questionnaire 
and who screened positive on TOP item 4a. Electronic reminders were sent (via 
email and online team calendar) on a weekly basis to case managers to undertake 
step 2 of the screening method. 
Eligible and consenting patients were assigned unique participant codes by 
the co-ordinator and these codes were then emailed to an independent assistant 
employed by the National Health Service who performed the random allocation. 
Randomisation was conducted using a computer generated random sequence 
which was concealed from the clinical teams and the study co-ordinator who 
undertook recruitment interviews. Participants were either randomized to receive 
BA or CBT based guided self-help, and this outcome was communicated to clinical 
administrators who then made contact with participants to offer them a treatment 
appointment. Outcomes data were collected by the study co-ordinator at 6, 12 and 
24 week follow-up to maximize data completeness. This follow-up method ensured 
that post-treatment outcomes were not collected by the therapists who delivered 
the intervention. The CONSORT diagram in Figure 1 summarizes all of the above 
steps and illustrates the flow of participants through the screening, randomization, 
treatment and follow-up phases. 
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Figure 1. CONSORT diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allocated to GSH (n= 27) ? Offered ‘co-located’ appointments (n=  27; 100%) ? Received allocated intervention (n= 13; 48.1%) ? Never attended appointments (n=  14; 51.9%) 
 
 
Allocated to BA (n= 23) ? Offered ‘parallel’ appointments (n=  13; 56.5%) ? Offered ‘co-located’ appointments (n=  10; 43.5%) ? Received allocated intervention (n=  8; 34.8%) ? Never attended appointments (n=  15; 65.2%) 
 
Screened but excluded (n= 136) ?   Met criteria but declined to participate (n= 23) ?   Not meeting inclusion criteria (n= 113) 
      Of whom:   
42.1% had disengaged with CDAT service 
36.8% had primary anxiety disorder 
21.1% had psychotic or bipolar disorder 
 
Analysed (n= 23) ? Baseline data for 4 cases lost to follow-up were 
included in analysis using IPW method 
 
Lost to follow-up (n= 4) 
 
Lost to follow-up (n= 7) 
Analysed (n= 27)  ? Baseline data for 7 cases lost to follow-up were 
included in analysis using IPW method 
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68% of eligible 
Total approached for screening (n= 207) of whom:  
186 were screened 
17 refused screening 
4 screening was inappropriate at the time 
73 met inclusion criteria 
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2.4. Interventions 
2.4.1. Behavioral activation (BA) 
A 12-session BA intervention was delivered by qualified (to post-graduate 
level in structured guided self-help interventions, 1 year supervised clinical 
training course) and experienced psychological wellbeing practitioners offering low 
intensity treatments in a Primary Care Mental Health Service aligned to the English 
Improving Access to Psychological Therapies (IAPT) programme. BA is a structured 
intervention for depression based on principles of operant conditioning, functional 
analysis of behavior and problem solving (Hopko, Lejuez, Ruggiaro & Eifert, 2003; 
Martell, Addis & Jacobson, 2001). Essentially, it consists of: (a) self-monitoring to 
identify depressive and maladaptive behaviors; (b) graded scheduling of activities 
aiming to increase and reinforce adaptive behavior patterns; (c) reducing the 
frequency of avoidant behaviors, rumination and maladaptive coping strategies. 
The intervention followed a structured treatment manual developed by our 
collaborators for use in clinical trials of BA (Ekers, Richards, McMillan, Bland & 
Gilbody, 2011), with some additional examples and worksheets that are relevant to 
working with drug and alcohol users (timeline assessment of addiction and 
emotional problems, decisional balance sheets) drawn from a previous trial of dual 
diagnosis interventions (Hughes et al., 2008). 
BA was delivered in two settings. During the first half of the study, 
participants assigned to this intervention were offered appointments in primary 
care mental health clinics across the city (we called this ‘parallel’ care) as is usual 
for patients who access the IAPT programme. During the second half of the study, 
new BA participants were offered appointments in clinic rooms that were based 
within the CDAT services (we called this ‘co-located’ care). This aspect of the study 
design enabled us to investigate whether the location of care made any difference 
to engagement with therapy. For logistical reasons (e.g. the need to obtain and 
regularly use a clinic room in addiction settings, the impact of travelling on 
psychological therapists’ time and wider caseloads), it was more practical to switch 
to co-located  care halfway through the study, rather than to individually 
randomize BA participants to parallel vs. co-located treatments. 
 
2.4.2. Guided self-help (GSH) 
The GSH intervention was much more minimal in terms of length and 
intensity, since it involved a single 1 hour session delivered by a non mental health 
specialist. This involved asking trained case managers employed by CDAT services 
to provide, describe and encourage participants to apply a self-help booklet for 
depression based on principles of CBT (Newcastle North Tyneside and 
Northumberland Mental Health NHS Trust, 2012). In brief, the booklet introduces 
readers to common thinking biases, thought challenging techniques, self-
monitoring and goal setting. The intervention concludes with homework 
assignments (e.g. to finish reading the booklet and to apply it on a daily basis). All 
GSH appointments were ‘co-located’ in usual CDAT clinics. 
 
2.5. Measures 
The Patient Health Questionnaire (PHQ-9) was used to screen for symptoms 
of depression and as a primary outcome measure. This is a nine-item self-
completed questionnaire based on the Diagnostic and Statistical Manual (DSM-IV) 
diagnostic criteria for major depressive disorder (Kroenke, Spitzer & Williams, 
2001). Each item is rated on a 0 to 3 scale relating to the frequency of depressive 
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symptoms over the last two weeks (0 = ‘not at all’ to 3 = ‘nearly every day’). Scores 
range from 0 to 27 with higher scores indicating greater severity. A cut-off score ≥ 
12 has been found to have adequate sensitivity (81%) and specificity (75%) for the 
detection of a current depressive episode in routine addiction treatment; the 
measure also has reliable temporal stability (ICC = .78) in this setting which 
supports its use for outcome monitoring (Delgadillo et al., 2011).  
Given that anxiety symptoms commonly co-occur with depression and 
impact on clinical outcome (Barlow, 2002), we also included the seven-item GAD-7 
questionnaire (Spitzer, Kroenke, Williams & Lowe, 2006) to screen potential 
participants for a severe anxiety disorder which may render them ineligible for the 
trial interventions. The GAD-7 is scored in the same way as the PHQ-9, with a 
range between 0 – 21. This scale has been established as a valid and reliable case-
finding measure for a variety of anxiety disorders in alcohol and drug users using a 
cut-off ≥ 9 (Delgadillo, 2012a). 
 The Treatment Outcomes Profile (TOP) is a validated questionnaire that 
captures information about substance use in the last 4 week period using the 
timeline follow-back method (Marsden et al., 2008). This questionnaire is routinely 
applied at regular intervals (e.g. 3 months) to monitor outcomes in addiction 
services (National Treatment Agency for Substance Misuse, 2012). The TOP also 
includes a brief psychological health scale (TOP item 4a) that has been 
demonstrated to reliably detect the presence of a diagnosable common mental 
disorder (cut-off ≤ 12, sensitivity = 83%, specificity = 71%) when compared to a 
structured diagnostic interview (Delgadillo, Payne, Gilbody, & Godfrey, 2013). 
 Severity of dependence to the primary drug used was assessed using the 5-
item Severity of Dependence Scale (Gossop et al., 1995) which has been widely 
validated as a reliable case-finder for substance use disorders (Castillo, Saiz, Rojas, 
Vazquez & Lerma, 2010; Kaye & Darke, 2002; Lawrinson, Copeland, Gerber & 
Gilmour, 2007; Swift, Copeland & Hall, 1998). This scale renders a continuous 
severity score ranging from 0 – 15, where a score of 0 to 10 denotes mild-to-
moderate psychological dependence. 
 
2.6. Training and supervision 
Qualified BA therapists accessed 2 training days delivered by practitioners 
with expertise in behavior therapy (DE) and dual diagnosis (JD, LH), and had 
access to group and individual supervision (led by JD; 2 hours every 6 weeks) 
which was additional to their weekly clinical supervision in primary care. CDAT 
workers who delivered GSH accessed ½ day training with a counseling psychologist 
(SG) who also led their supervision group (1.5 hours every 6 weeks). All therapists 
were required to keep written records of sessions, which were inspected by the 
relevant supervisors. Due to limited study resources, no additional fidelity checks 
(such as independent analysis of recorded sessions) were possible.   
 
2.7. Data analysis 
2.7.1. Feasibility analysis 
Screening, recruitment, random allocation and treatment engagement data 
were summarized using a CONSORT diagram (Figure 1). In order to assess the 
integrity of randomization, demographic and clinical characteristics were compared 
between groups using chi-square tests for categorical variables, t-tests for normally 
distributed continuous variables and non-parametric Mann-Whitney U-tests for 
continuous variables with skewed distributions. 
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 In order to quantitatively assess the feasibility of screening, recruitment and 
successful treatment, we estimated the number needed to screen (NNS) in order to 
obtain one additional recruit and the number needed to treat (NNT) in order to 
attain reliable and clinically significant improvement with one patient. We were 
also interested in exploring potential predictors of engagement with psychological 
interventions, which was defined as having attended at least 1 therapy 
appointment. To this end, we applied multivariate logistic regression models 
predicting engagement (coded = 1) versus non-engagement (coded = 0), using 
backward elimination of variables with an alpha level of p > .05. Backward 
elimination was considered appropriate given the small number of participants and 
hence the likelihood that sample power would be insufficient to apply models that 
control for several variables. Potential predictors were demographics (age in 
quartiles, gender, ethnicity), treatment group (BA vs. GSH), appointment modality 
(co-located vs. parallel care), baseline symptom severity (PHQ-9, SDS), and baseline 
substance use variables (use of opiate substitute medication, PDA, binary marker 
for poly-substance use). Goodness-of-fit in these analyses was assessed using the 
Hosmer-Lemeshow test and by examining residual plots. 
 
2.7.2. Secondary analyses 
The outcome variable, change in the severity of depression symptoms (PHQ-
9) at endpoint follow-up, was compared between groups using analysis of 
covariance (ANCOVA). Since we expected difficulties with attrition and follow-up as 
is common in routine addiction treatment, the study design with multiple follow-up 
assessments enabled us to use the last available assessment as the endpoint for 
each participant (applying a last observation carried forward method). PHQ-9 
change scores were taken as the dependent variable in ANCOVA models. Change 
scores were calculated as the baseline minus the endpoint measure to make 
interpretation more intuitive, such that a positive score denotes improvement and 
a negative score denotes deterioration in depression symptoms. Group (BA vs. 
GSH) was entered as a fixed factor; baseline PHQ-9 score, age (categorized into 
quartiles), gender and time were entered as covariates. The time variable denoted 
the time interval (in weeks) between the baseline and final available measurement 
for each participant, which was variable considering differences in attrition and 
follow-up. The main analysis was conducted based on intention-to-treat principles. 
To account for cases with completely missing follow-up data (N = 11; 22.0%), 
inverse probability weighting (IPW) was used in the ANCOVA model as a sensitivity 
analysis. IPW has been recommended as an appropriate method to minimize bias 
that is common in complete-case analysis and is often preferable to multiple 
imputation (Hernán & Hernández-Díaz, 2012; Seaman & White, 2013). Between-
group differences were estimated, both in terms of mean and adjusted PHQ-9 
change scores and as standardized effect sizes (Cohen’s d). Within-group effect 
sizes were also calculated using the method proposed by Minami et al. (2008); this 
estimate is comparable to Cohen’s d, computed for repeated measures and 
weighted by sample size. 
Reliable and clinically significant improvement (RCSI) rates were calculated 
following the criteria proposed by Jacobson and Traux (1991) and based on a PHQ-
9 reliable change index (≥7) and cut-point (<12) calibrated for clinical samples of 
alcohol and drug users (Delgadillo, 2012). Between-group RCSI rates were 
compared using chi-square analysis. 
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 Changes in substance use (measured with TOP) were explored by estimating 
percent days abstinent (PDA) over the last 4 weeks for each case. Endpoint PDA 
change scores were calculated as described above and taken as the dependent 
variable in ANCOVA; with group as a fixed factor; and controlling for age 
(quartiles), gender, time, baseline SDS and baseline PDA. In this analysis, a 
negative change score would denote a reduction and a positive score would denote 
an increase in substance use. Associations between PDA and PHQ-9 change scores 
at follow-up were explored using Pearson’s correlations. Conventional assumptions 
to undertake ANCOVA analyses were verified using formal tests for homogeneity of 
variance and by inspecting residual plots. 
 
3. Results 
 
3.1. Sample characteristics and feasibility 
As shown in Figure 1, a total of 207 patients were approached for mental 
health screening during an 18 month period, based on their response to the TOP 
questionnaire which indicated that they potentially met criteria for a common 
mental disorder (TOP item 4a). More detailed screening using PHQ-9 was feasible 
with 186 patients (89.9% of 207), out of whom 73 (39.2% of screened cases) met 
criteria for the study but only 50 (68.5% of eligible cases) consented to participate. 
Based on these observations, we estimate that it is necessary to screen 4 patients 
to successfully recruit and randomize one consenting and eligible participant (207 
/ 50 = 4.14 = number needed to screen). 
Consenting participants were mostly white British (72.0%) males (68.0%), 
with a mean age of 37.2 (SD = 6.6), most of whom were currently prescribed opiate 
substitute medication (92.0%) and anti-depressants (64.0%). The most commonly 
used substances in this sample were alcohol (50.0%), heroin (34.0%), crack (22.0%) 
and cannabis (22.0%). Table 1 presents detailed sample characteristics and 
demonstrates that there were no significant differences between the BA (N = 23) 
and GSH (N = 27) groups in any of these characteristics, except for mean baseline 
SDS which appeared to be higher in the BA group; U(50) = 202.00, p = .03. 
Importantly, there were no significant differences in baseline PHQ-9 between those 
who provided follow-up data (mean = 16.72, SD = 4.48) and those who did not 
(mean = 17.91, SD = 3.75); t(48) = -0.80, p = .42. There were no significant 
differences in mean PDA estimates between participants who were followed-up 
(mean = 0.38, SD = 0.38) and those who were lost to follow-up (mean = 0.19, SD = 
0.24); t(26) = 1.96, p = .06. Overall, the randomization process successfully 
produced two groups with comparable baseline characteristics, and there was no 
evidence of bias introduced by cases lost to follow-up. 
Only 21 participants (42.0%) actually engaged with their allocated 
intervention (defined as attending at least one session). There were no significant 
differences in engagement between the BA (N = 8; 34.8%) and GSH (N = 13; 48.1%) 
groups; x2(1) = 0.91, p = .34. Those who engaged with BA attended a mean number 
of 3.13 sessions (SD = 1.73, mode = 5). A closer examination of the group of BA 
participants that engaged in treatment revealed that those offered co-located care 
(N = 5; 62.5%) attended a higher mean number of total therapy sessions (mean = 
4.20, SD = 1.10) compared to those offered parallel care (N = 3, 37.5%, mean = 
1.33, SD = .58); however the small numbers did not allow us to formally apply tests 
of statistical significance. All of those who engaged with GSH had only 1 session (as 
per protocol), except for one participant who required 2 sessions to work through 
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the self-help booklet due to obstacles with concentration and literacy. We explored 
potential predictors of engagement using multivariate logistic regression. The final 
logistic regression model reached through a two-step process of backward 
elimination of variables is presented in Table 2. According to this model, poly-
substance users were significantly less likely to engage with therapy (Odds ratio = 
.15, p = .02) and patients offered ‘co-located’ appointments in a CDAT clinic (who 
accessed GSH or co-located BA) were at least 7 times more likely to engage 
compared to participants offered BA in general primary care mental health clinics 
(Odds ratio = 7.14, p = .04). 
 
 
 
Table 1.  
Sample characteristics and comparisons between randomly assigned groups 
 
 Full sample 
N=50 (100%) 
BA 
N=23 (46%) 
GSH 
N=27 (54%) 
test 
statistic 
p 
Demographics  
Males 34 (68.0) 18 (78.3) 16 (59.3) x2(1)=2.06 .15 
Mean age (SD) 37.2 (6.6) 38.4 (6.2) 36.2 (6.8) t(48)=1.23 .22 
Ethnicity      
       White British 36 (72.0) 16 (69.6) 20 (74.1) x2(1)=0.13 .72 
       Other 14 (28.0) 7 (30.4) 7 (25.9)   
Substances used in the last month 
Alcohol 25 (50.0) 14 (60.9) 11 (40.7) x2(1)=2.01 .16 
       Mean units per week (SD) 42.9 (56.4)** 53.9 (73.3)** 30.9 (30.0)** U(23)=61.00 .76 
Heroin 17 (34.0) 5 (21.7) 12 (44.4) x2(1)=2.85 .09 
       Mean g. per week (SD) .29 (.33)** .15 (.13)** .34 (.37)** U(16)=32.50 .27 
Crack 11 (22.0) 3 (13.0) 8 (29.6) x2(1)=1.99 .16 
       Mean g. per week (SD) .19 (.13)** .10 (.00)** .22 (.14)** U(11)=19.50 .09 
Cannabis 11 (22.0) 6 (26.1) 5 (18.5) x2(1)=0.42 .52 
       Mean spliffs per week (SD) 10.3 (9.4)** 7.7 (10.3)** 13.4 (8.1)** U(11)=22.50 .17 
Other 4 (8.0) 4 (17.4) 0 -  
Poly-substance use 18 (36.0) 7 (30.4) 11 (40.7) x2(1)=0.72 .40 
Injecting 6 (13.6)* 3 (15.0)* 3 (12.5)* -  
Abstinent 9 (18.0) 4 (17.4) 5 (18.5) -  
Severity of dependence and psychological symptoms at screening 
SDS mean (SD) 6.1 (3.7) 7.3 (3.8) 5.1 (3.4) U(50)=202.00 .03 
PHQ-9 mean (SD) 16.9 (4.3) 17.61 (4.7) 16.4 (4.0) t(48)=-0.95 .35 
GAD-7 mean (SD) 11.9 (4.7) 12.3 (4.0) 11.6 (5.3) t(48)=0.50 .62 
TOP-4a mean (SD) 8.5 (3.5)* 8.7 (3.6) 8.3 (3.4)* t(47)=0.39 .70 
Treatment 
Mean no. weeks in treatment 
(SD) 
195.3 
(119.1)* 
202.9 
(126.5)* 
189.3 
(115.1)* 
t(43)=0.38 .71 
Using opiate substitute 
prescription 
46 (92.0) 21 (91.3) 25 (92.6) -  
Using antidepressants 32 (64.0) 14 (60.9) 18 (66.7) x2(1)=0.18 .67 
Engaged with trial intervention† 21 (42.0) 8 (34.8) 13 (48.1) x2(1)=0.91 .34 
* Estimates exclude missing data; ** estimates exclude abstainers from each substance; † refers to 
participants who attended at least 1 session of allocated intervention; t = Student’s t-test; U -Whitney 
U test; x2 = Chi-square test; - denotes missing estimates due to violation of test assumptions 
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Table 2.  
Step-wise logistic regression modelling strategy to identify predictors of 
engagement* with psychological interventions 
 
 Step 1  Step 2 
 pseudo R2 = .45  pseudo R2 = .35 
Variable B SE β p  B SE β p 
(Constant) -23.59 28235.63 <.001 .99  -1.42 1.15 .24 .22 
Gender † 1.34 1.26 3.82 .29  .53 .82 1.70 .51 
Age lowest quartile 
(≤32) 
   .60     .77 
Age quartile 2 (33-36) -.28 1.52 .76 .85  -.09 1.02 .92 .93 
Age quartile 3 (37-43) 1.65 1.54 5.19 .28  .27 1.01 1.31 .79 
Age quartile 4 (≥44) .99 1.45 2.69 .50  1.07 1.17 2.90 .36 
Poly-substance use † -2.35 1.18 .10 .04  -1.90 .79 .15 .02 
Modality † 3.47 1.73 31.98 .04  1.97 .98 7.14 .04 
Psychological 
treatment group † 
1.26 1.53 3.53 .41      
Ethnicity † -1.40 1.45 .25 .33      
Opiate substitute 
treatment † 
19.37 28235.63 258202165.3 .99      
Baseline PHQ-9 .03 .14 1.03 .82      
Baseline SDS .01 .15 1.01 .97      
Baseline PDA 1.22 1.51 3.39 .42      
* Engagement is defined as having accessed at least one session of the allocated intervention; step 1 
entered all potential predictors of engagement, while step 2 presents a more parsimonious model in 
which non-significant predictors were removed by backward elimination; 
† Reference categories: Gender = male; Age = lowest quartile; poly-substance use = non poly-use; 
modality = parallel care; psychological treatment group = CBT guided self-help; ethnicity = white 
British; opiate substitute treatment = not using; β = odds ratio 
 
 
3.2. Depression symptom outcomes 
The intention-to-treat (ITT) ANCOVA analysis predicting change in 
depression symptoms (PHQ-9) at follow-up found no significant main effects for 
treatment group after controlling for covariates; F(1, 33) = .29, p = .59. The 
sensitivity analysis applying inverse probability weighting (IPW) to assess the 
influence of missing data also confirmed the same result; F(1, 33) = .06, p = .81. 
Only baseline PHQ-9 was a significant predictor of change in depression symptoms 
in the ANCOVA models; ITT model, F(1, 33) = 8.89, p < .01; IPW model, F(1, 33) = 
9.66, p < .01. Table 3 presents unadjusted and adjusted mean estimates of PHQ-9 
change scores for each group. The mean difference -1.06 (95% CI = -5.05, 2.92) 
reflects an approximate between-groups effect size of d = -0.64 favoring GSH, 
although this was not statistically significant (p = .59). Baseline and endpoint mean 
scores and standard deviations reported in Table 3 were used to estimate within-
group effect sizes weighted by sample size; these were d = .49 for BA and d = .63 
for GSH. The proportions of patients meeting criteria for reliable and clinically 
significant improvement (RCSI) were 11.8% for BA and 22.2% for GSH, although 
differences were not statistically significant; x2(1) = 0.67, p = .41. The overall 
proportion of participants meeting RCSI criteria across both treatment groups was 
17.1%, and the approximate number needed to treat in order to obtain full recovery 
with one patient was 6 (NNT = 5.83). 
3.3. Substance use outcomes 
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The ITT ANCOVA model predicting change in percentage days abstinent 
(PDA in the last month) at follow-up found no significant main effects for treatment 
group after controlling for covariates; F(1, 28) = 3.32, p = .08. This finding was 
corroborated by the IPW ANCOVA model; F(1, 28) = 3.82, p = .06. Baseline PDA 
significantly predicted changes in endpoint PDA estimates in the ANCOVA models; 
ITT model, F(1, 28) = 12.10, p < .01; IPW model, F(1, 28) = 10.29, p < .01. The 
mean difference shown in Table 3 was .25 (95% CI = -.03, .52), which reflects an 
approximate between-groups effect size of d = 1.52 favoring BA, although this was 
not statistically significant (p = .08). Baseline and endpoint estimates reported in 
Table 3 were used to calculate within-group effect sizes weighted by sample size; 
these were d = .40 for BA and d = .02 for GSH. No significant associations were 
found between PDA change and PHQ-9 change scores at follow-up; r = 0.10, p = 
.57. 
 
 
Table 3.  
Change in depression (PHQ-9) and percentage days abstinent (PDA) in each of 
the treatment conditions 
 
Group Baseline 
mean  
(SD) 
End-point 
mean  
(SD) 
Unadjusted 
mean 
change score 
(SE) 
Adjusted* 
mean 
change score 
(SE) 
Mean Difference 
(95% CI) 
p 
Depression (PHQ-9) 
BA 
(N = 19) 
17.61 (4.66) 15.21 (5.41) 1.79 (1.48) 1.69 (1.32) -1.06 (-5.05, 2.92) .59 
GSH 
(N = 20) 
16.44 (4.02) 13.80 (5.36) 2.65 (1.20) 2.75 (1.28)   
Percentage days abstinent during the last month (PDA) 
BA 
(N = 15) 
.38 (.40) .55 (.45) .12 (.13) .17 (.10) .25 (-.03, .52) .08 
GSH 
(N = 20) 
.30 (.33) .30 (.34) -.04 (.08) -.08 (.08)   
* Adjusted for PHQ-9 baseline severity, age, gender, follow-up time, using intention-to-treat analysis; 
BA = Behavioural Activation; GSH = Guided self-help based on cognitive behavioural therapy booklet; 
SE = standard error; CI = 95% confidence intervals; N = denotes the total number of respondents with 
complete follow-up data per group and outcome of interest 
 
 
4. Discussion 
 
4.1. Main findings 
This phase I feasibility trial applied a high volume, structured and stepwise 
mental health screening method to identify CDAT patients with clinically 
significant depression symptoms. Based on this strategy, the ratio of screened to 
recruited patients was 4 to 1. Our results demonstrated the integrity of the random 
allocation method and it was possible to follow up 78% of study participants post-
treatment. Overall, it was feasible to conduct a trial embedded within busy clinical 
settings, maximizing the external validity of the study design. A noteworthy aspect 
of the study design is the demonstration that high volume screening of mental 
health problems can be feasibly embedded within routine CDAT services, and 
linked with evidence-based psychological treatments. The first point potentially 
offers an important advance, since consistent and reliable mental health screening 
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is known to be lacking in routine addiction services (Weaver et al., 2003). Our 
pragmatic approach also resembles recent studies aiming to train addiction 
treatment workers to use screening tools and to offer brief interventions for 
depressed substance users (e.g. see Lee et al., 2011; Watkins, Paddock, Zhang, & 
Wells, 2006). 
The greatest difficulty we encountered was the high attrition rate resulting 
in poor engagement with treatment. This was in spite of the additional 
administrative support available to the research team which was used to 
proactively chase up study participants to try to maximize engagement. Our 
findings revealed that poly-substance use was a risk factor for non-engagement in 
this sample. Most poly-substance users in this study were combining heroin and 
crack-cocaine, which is consistent with research indicating that this combination 
of drugs is associated with treatment discontinuation (Leri, Bruneau, & Stewart, 
2003). However, readers should also consider that other studies have yielded mixed 
evidence about the associations between treatment attrition and quantity, 
frequency and type of substance use (e.g. see review by Stark, 1992). It may be that 
poly-substance use could be a marker for other complex factors that influence 
engagement with treatment, for example impulsivity, involvement in criminal 
activity, impairments in social adjustment, etc. Such potential associations 
warrant further investigation. We also found that offering appointments co-located 
in the CDAT setting considerably increased the likelihood of engagement. 
Furthermore, it appears that co-located care may also result in greater number of 
attended therapy sessions by comparison to parallel care. A possible explanation 
may be that co-location in a familiar setting minimizes clients’ concerns about 
privacy or stigma related to mental health problems. For instance, concerns about 
privacy have been previously endorsed by patients as a reason for dropping out of 
addictions treatment (Ball, Carroll, Canning-Ball, Rounsaville, 2006). Another 
possibility is that co-location simply makes access to treatment more convenient, 
especially if patients may have limited financial resources to travel to various 
appointments in different locations. 
The preliminary outcomes analysis evidenced modest improvements in 
depression symptoms over time, with moderate within-group effect sizes (d = .49 to 
.63). These effects are comparable in magnitude to the BA trial conducted by 
Daughters et al. (2008), where the approximate within-group pre-post effect sizes 
for the BA intervention were d = 0.49 for the Hamilton Depression Scale and d = 
0.91 for the Beck II Depression measure. Considering the wider literature in this 
area, Hesse (2009) reported aggregated depression symptom effect sizes in the 
region of d = -0.58 (95% CI -1.10 to -0.06) in a meta-analysis favoring integrated 
psychological and substance use disorder treatments compared to non-integrated 
control conditions. A more recent meta-analysis (Riper et al., 2014) which 
specifically focused on integrated CBT and motivational interviewing trials (iCBT) 
reported a more modest aggregated effect size for depression symptoms favoring 
iCBT versus usual care (g = 0.27, 95% CI 0.13 to 0.41).  
As noted by Hides et al. (2010) trials comparing CBT to active control 
conditions in depressed substance users mostly report non-significant differences. 
Similarly, we found no significant differences in depression symptom outcomes 
between groups, which was remarkable considering that the GSH intervention was 
delivered over a considerably briefer duration (1 session). However, this finding 
should be taken as preliminary since this study was not sufficiently powered to 
undertake a non-inferiority analysis. It is also possible that the non-significant 
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differences may be explained by the relatively low number of mean treatment 
sessions (mean = 3.13, mode = 5) attended by participants in the BA group. We 
note that the PDA estimate increased by 17% in the BA group after treatment, 
indicating reduction in substance use, whereas no change in substance use was 
apparent in the GSH group. This finding requires replication in a larger sample 
since the mean difference between groups did not reach statistical significance. It 
nevertheless raises an interesting question about the potential benefit of BA in the 
reduction of problematic substance use, which is comparable in effect to the 
average 14.1% PDA gain reported in the meta-analysis by Hesse and collaborators 
(Hesse, 2009) favoring integrated psychological interventions. 
  
4.2. Implications for practice and research 
The psychological care of dependent substance users has historically tended 
to be a neglected area of practice and research. The present study draws attention 
to the feasibility of high volume mental health screening, and the co-location of 
psychological and substance use interventions. 
 Co-location of mental health and addiction specialists appears to enhance 
engagement with treatment and is consistent with policy developments urging 
professionals to co-ordinate care and break down barriers for people with complex 
needs and co-morbidities (Department of Health, 2002; Mental Health Foundation, 
2013). We underline two further points about co-location. First, future trials could 
investigate whether it is possible to maximize the benefit of co-location by applying 
principles of contingency management (CM), which involves the provision of 
incentives (e.g. vouchers, or prescriptions) to enhance treatment adherence. CM 
has a robust evidence base in addictions treatment and is recommended by clinical 
guidelines (National Institute for Health and Clinical Excellence, 2007). For 
example, co-located depression treatment appointments followed by CM specifically 
aimed to incentivize (a) attendance and (b) abstinence may provide the best 
possible context to enable patients to self-manage their mental health. Secondly, 
the parallel care offered in our trial was far more costly and less efficient due to lost 
clinical time, additional administrative burden invested in chasing participants up 
and additional clinical time invested in calling and liaising with workers in CDAT 
services. Future trials and indeed clinical practice should consider either co-
locating mental health specialists within CDAT services or training and supervising 
addiction workers to deliver evidence-based interventions for depression 
symptoms. 
 
4.3. Limitations 
The stepwise screening method may have excluded some potentially eligible 
participants simply due to the limitations of the TOP item 4a scale which was 
applied as the first step, since some ‘false negatives’ may have been excluded from 
screening with PHQ-9. This is a plausible limitation; however, our decision to apply 
a pragmatic stepwise method is congruent with our prior observations that some 
patients can find detailed screening intrusive and emotionally challenging 
(Delgadillo et al., 2012b). We therefore argue that stepwise screening achieves an 
adequate balance between reliability, acceptability and feasibility in busy clinical 
settings. It is also possible that the study sample may be less representative of 
more severely distressed and impaired substance users, since we excluded those 
patients with severe symptoms of dependence (defined by the SDS measure). The 
rationale for this exclusion was to ensure that participants were reasonably stable 
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on medication and engaged in addiction treatment by the time they had an 
opportunity to take part in the study. A further consideration about the screening 
and recruitment method is that our pragmatic case-finding and recruitment 
strategy introduced a low threshold for inclusion in the study, since we set out to 
find participants that may not otherwise have been treatment seekers. Indeed, this 
low threshold meant that we had to exclude a number of patients who were 
screened but turned out to have primary anxiety, psychotic or bipolar disorders as 
illustrated in Figure 1. We also note that nearly half of the patients that were 
screened but excluded from participating in the trial had either declined therapy or 
generally disengaged with the wider CDAT intervention. 
 Despite the considerable number of participants who did not engage with 
treatment, we managed to obtain follow-up data from 78% using a last observation 
carried forward (LOCF) method. It is of course possible that our estimations of end-
point outcomes may be inaccurate since the LOCF method assumes that no 
change has occurred since the last available assessment. Missing follow-up data is 
a common limitation in clinical trials involving substance users with mental health 
problems (Hesse, 2009). Nevertheless, we ensured a robust analysis by applying 
intention-to-treat principles and inverse probability weighting to account for 
missing data. A further limitation concerns the lack of formal fidelity checks over 
and above regular case reviews and supervision, which was not possible to 
undertake within the financial constraints of this study. 
 
4.4. Concluding remarks 
Overall, this study demonstrates that integrating stepwise mental health screening 
in routine addiction treatment is feasible and can be linked with cognitive and 
behavioral interventions, ideally co-located in the same setting to maximize 
engagement. As others have argued (Morisano, Babor & Robaina, 2014; Torrens, 
Rossi, Martinez-Riera, Martinez-Sanvisens & Bulbena, 2012) we take the view that 
system level, public health oriented, screening and psychological interventions 
integrated within CDAT are needed to improve the mental health and functioning of 
patients. 
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